Prediabetes Market Size, Share & Trends Report

Prediabetes Market (2025 - 2030) Size, Share & Trends Analysis Report By Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), By Age Group (Children, Adult, Elderly), By Region, And Segment Forecasts

Market Segmentation

Prediabetes Drug Class Outlook (Revenue, USD Million; 2018 - 2030)
- Diguanide
- Thiazolidinediones
- Glucagon-like peptide-1 agonists (GLP-1)
- SGLT2 inhibitors
- DPP-4 inhibitors
- Others
Prediabetes Age Group Outlook (Revenue, USD Million; 2018 - 2030)
- Children (12-18 years)
- Adults (18-49)
- Elderly (50+)
Prediabetes Regional Outlook (Revenue, USD Million; 2018 - 2030)
- North America
  - North America Prediabetes Market, By Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - North America Prediabetes Market, By Age Group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - U.S.
    - U.S. Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - U.S. Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Canada
    - Canada Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Canada Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Mexico
    - Mexico Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Mexico Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
- Europe
  - Europe Prediabetes Market, By Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - Europe Prediabetes Market, By Age Group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - UK
    - UK Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - UK Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Germany
    - Germany Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Germany Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - France
    - France Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - France Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Italy
    - Italy Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Italy Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Spain
    - Spain Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Spain Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Denmark
    - Denmark Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Denmark Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Norway
    - Norway Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Norway Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Sweden
    - Sweden Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Sweden Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
- Asia Pacific
  - Asia Pacific Prediabetes Market, By Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - Asia Pacific Prediabetes Market, By Age Group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - Japan
    - Japan Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Japan Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - China
    - China Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - China Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - India
    - India Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - India Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - South Korea
    - South Korea Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - South Korea Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Australia
    - Australia Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Australia Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Thailand
    - Thailand Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Thailand Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
- Latin America
  - Latin America Prediabetes Market, By Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - Latin America Prediabetes Market, By Age Group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - Brazil
    - Brazil Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Brazil Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Argentina
    - Argentina Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Argentina Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
- Middle East & Africa
  - Middle East & Africa Prediabetes Market, By Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - Middle East & Africa Prediabetes Market, By Age Group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - South Africa
    - South Africa Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - South Africa Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Saudi Arabia
    - Saudi Arabia Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Saudi Arabia Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - UAE
    - UAE Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - UAE Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Kuwait
    - Kuwait Prediabetes Market, By Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Kuwait Prediabetes Market, By Age Group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments